The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury - Sorbonne Université
Journal Articles Frontiers in Pharmacology Year : 2021

The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury

Frédéric Jaisser
Xiaojuan Tan
  • Function : Author
Shuangshuang Chi
  • Function : Author
Jinrong Liu
  • Function : Author
Ping Wang
  • Function : Author
Vincent Benn
  • Function : Author
Y. Fred Fred Yang
  • Function : Author
Jay Zhang
  • Function : Author

Abstract

The therapeutic indices (TIs) and efficacy of the non-steroidal mineralocorticoid receptor antagonist (MRA) KBP-5074 and steroidal MRA eplerenone were evaluated in a uninephrectomized Sprague Dawley rat model of aldosterone-mediated renal disease. In two parallel studies, rats were placed on a high-salt diet and received aldosterone by osmotic mini-pump infusion over the course of 27 days. The urinary albumin-to-creatinine ratio (UACR) was evaluated after 7, 14, and 26 days of treatment. Serum K + was evaluated after 14 and 27 days of treatment. Urinary Na + , urinary K + , and urinary Na + /K + ratio were evaluated after 7, 14, and 26 days of treatment. The TI was calculated for each drug as the ratio of the concentration of drug producing 50% of maximum effect (EC 50) for increasing serum K + to the EC 50 for lowering UACR. The TIs were 24.5 for KBP-5074 and 0.620 for eplerenone, resulting in a 39-fold improved TI for KBP-5074 compared with eplerenone. Aldosterone treatment increased UACR, decreased serum K + , and decreased urinary Na + relative to sham-operated controls that did not receive aldosterone infusion in both studies, validating the aldosterone/salt renal injury model. KBP-5074 prevented the increase in UACR at 0.5, 1.5, and 5 mg/kg BID while eplerenone did so only at the two highest doses of 50 and 450 mg/kg BID. Both KBP-5074 and eplerenone blunted the reduction in serum K + seen in the aldosterone treatment group, with significant increases in serum K + at the high doses only (5 mg/kg and 450 mg/kg BID, respectively). Additionally, the urinary Na + and Na + /K + ratio significantly increased at the middle and high doses of KBP-5074, but only at the highest dose of eplerenone. These results showed increased TI and efficacy for KBP-5074 compared with eplerenone over a wider therapeutic window.
Fichier principal
Vignette du fichier
fphar-12-604928.pdf (1.51 Mo) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

hal-03285721 , version 1 (13-07-2021)

Identifiers

Cite

Frédéric Jaisser, Xiaojuan Tan, Shuangshuang Chi, Jinrong Liu, Ping Wang, et al.. The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury. Frontiers in Pharmacology, 2021, 12, ⟨10.3389/fphar.2021.604928⟩. ⟨hal-03285721⟩
48 View
54 Download

Altmetric

Share

More